{"id":"azd6244-dosing-period-1","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"31%","effect":"Nausea"},{"rate":"21%","effect":"Vomiting"}]},"status":"active","trials":["NCT01635023"],"aliases":["AZD6244"],"patents":[],"pricing":[],"timeline":[],"aiSummary":"MEK inhibitor Used for Non-small cell lung cancer.","brandName":"AZD6244 Dosing Period 1","companyId":"astrazeneca","mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD6244 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.","oneSentence":"MEK inhibitor","_ai_confidence":"high"},"commercial":null,"companyName":"AstraZeneca","competitors":[],"genericName":"AZD6244 Dosing Period 1","indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}